MRK Merck & Company Inc
Company Analysis
Latest News
Merck Tulisokibart Hits Phase 3 Goal, First-in-Class Success for Ulcerative Colitis
Merck reported positive topline results from the Phase 3 ATLAS-UC induction-only study for tulisokibart. This investigational treatment targets patients with...
🔴 Merck & Company Inc is trading 3.1% down today despite expanded CAPVAXIVE FDA approval
Merck & Company Inc is trading 3.1% down at $111.83 despite announcing expanded FDA approval for its CAPVAXIVE pneumococcal vaccine in high-risk children and...
Merck Expands CAPVAXIVE FDA Approval to High-Risk Children and Teens
Merck received FDA approval for the expanded use of its pneumococcal vaccine, CAPVAXIVE. The new indication covers children and adolescents aged 2 through 17...
Merck Shares Fall 3%, Medicare Rule Targets Keytruda Patent Loophole
Merck & Co. (MRK) shares fell over 3% on June 15. The Centers for Medicare & Medicaid Services (CMS) proposed a permanent framework for negotiating drug...
Merck Wins FDA Approval for Kidney Cancer Combo, Slashing Recurrence Risk
The FDA approved Merck’s Welireg (belzutifan) in combination with Keytruda (pembrolizumab) for adult patients with renal cell carcinoma (RCC). The treatment...
Merck and Gilead Scrap Keytruda Combination Trial, Citing Efficacy Shortfall
Merck and Gilead Sciences discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 study. The trial evaluated a combination of Keytruda and Trodelvy for metastatic...
Merck and Gilead Report Success for First Once-Weekly Oral HIV Pill
Merck and Gilead Sciences announced positive topline results from two Phase 3 trials, ISLEND-1 and ISLEND-2. The studies evaluated a once-weekly oral...
Merck faces Keytruda patent cliff, ending the era of blockbuster cancer drugs
Merck’s Keytruda faces a patent cliff in 2028. This milestone signals the end of the single, dominant blockbuster era in oncology. The market is shifting...
🟢 Merck & Co Inc is trading 5.1% up today on pipeline optimism and broader defensive market rotation
Merck & Company Inc is trading 5.1% up at $120.52, benefiting from positive pipeline developments and a broader market shift into defensive and healthcare...
🟢 Merck & Company Inc is trading 3.4% up today on defensive rotation and positive analyst sentiment
Merck & Company Inc is trading 3.4% up at $118.57 as the stock benefits from a rotation into defensive, value-oriented names within the Dow. • The stock is...
🟢 Merck & Company Inc is trading 4.16% up
MRK is trading at $119.47, up 4.16%.
🔴 Merck & Company Inc is trading 3.18% down today after mixed ASCO oncology data and profit-taking
Merck & Company Inc is trading at $114.95 (-3.18%) following mixed oncology news flow from the ASCO conference and a broader reset in investor expectations. •...
Merck Secures $4 Billion Norges Bank Stake Following FDA Cancer Drug Win
Norges Bank, Norway’s central bank, purchased approximately 37.98 million shares of Merck. This stake is valued at roughly $4.0 billion. The investment gives...
Merck Secures FDA Breakthrough Status for Calderasib-Keytruda Lung Cancer Combo
Merck announced the FDA granted Breakthrough Therapy Designation to its investigational drug calderasib (MK-1084). The designation covers calderasib in...
CVC Bids $12.4B for Recordati, Merck Lung Cancer Trial Cuts Risk 65%
A consortium led by CVC Capital Partners and Groupe Bruxelles Lambert launched a €10.7 billion ($12.4 billion) cash bid for Italian drugmaker Recordati. The...
Merck's first quarter 2026 revenue grew 5% on KEYTRUDA strength, prompting a raise in full-year guidance.
Merck reported first quarter 2026 sales of $16.3 billion, a 5% increase year-over-year, driven by its Oncology and Animal Health divisions. The company posted...
Merck & Company Inc Q1 2026 Earnings Preview: What Analysts Expect on April 30, 2026
Wall Street expects Merck & Co. to report first-quarter 2026 revenue of approximately $15.90 billion and a consensus EPS loss of $1.51, while the stock...
Big Pharma buys smaller biotechs, boosting sector stocks to fill pipelines
Large pharmaceutical companies are prioritizing strategic bolt-on acquisitions over megadeals. These transactions typically range in the low-single-digit...